Skip to main content

Systemic Mastocytosis News

Related terms: Mastocytosis, Systemic, Systemic Mast Cell Disease

FDA Approves Imkeldi (imatinib) Oral Solution for the Treatment of Certain Forms of Leukemia and Other Cancers

CAMBRIDGE, Mass.-- November 25, 2024 --Shorla Oncology (‘Shorla’), a U.S.-Ireland specialty pharmaceutical company, announced today that the FDA has approved Imkeldi (imatinib) oral solution, the fir...

FDA Approves Ayvakit (avapritinib) as the First and Only Treatment for Indolent Systemic Mastocytosis

CAMBRIDGE, Mass., May 22, 2023 /PRNewswire/ – Blueprint Medicines Corporation (Nasdaq: BPMC) today announced that the U.S. Food and Drug Administration (FDA) has approved Ayvakit® (avapritinib) for ...

FDA Approves Blueprint Medicines' Ayvakit (avapritinib) for the Treatment of Adults with Advanced Systemic Mastocytosis

First precision therapy that specifically targets the primary driver of the disease Durable clinical responses, including complete remissions, shown in patients with or without prior treatment Full...

FDA Approves Rydapt (midostaurin) for FLT3-Mutated Acute Myeloid Leukemia and Systemic Mastocytosis

April 28, 2017 – The U.S. Food and Drug Administration today approved Rydapt (midostaurin) for the treatment of adult patients with newly diagnosed acute myeloid leukemia (AML) who have a specific...

Ask a question

To post your own question to our community, sign in or create an account.

Further information

Related drug support groups

omeprazole, Prilosec, lansoprazole